Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

August 11, 2017: By Jon Swedien

Ocular Therapeutix logoOcular Therapeutix’ cash, cash equivalents, and marketable securities totaled $66 million at the end of Q2-2017, the Bedford, Massachusetts, company announced Aug. 8.

Cash used in operating activities was $11.3 million in Q2-2017, compared with $9.8 million in Q2-2016, Ocular Therapeutix said. Total costs and operating expenses for Q2-2017 were $18.8 million, compared with $11.5 million in Q2-2016, the company said.

Ocular Therapeutix reported a net loss of approximately $18.7 million in Q2-2017, compared with a net loss of $11.4 million in Q2-2016. The Q2-2017 results include $2.1 million in non-cash charges for stock-based compensation and depreciation, compared with $1.7 million in such non-cash charges in Q2-2016.

The company is working to obtain approval for its lead product candidate, Dextenza, a proposed treatment for pain after ophthalmic surgery.

In mid-July, Ocular Therapeutix received a complete response letter (CRL) from the US FDA for its resubmitted new drug application (NDA) for Dextenza due to deficiencies in manufacturing and testing.

It was Dextenza’s second CRL related to plant issues.

Ocular Therapeutix made $400 thousand in revenues during Q2-2017 from product sales of ReSure Sealant, a product indicated for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022